Paper - WANFANG MED ONLINE

You Position: Home > Paper

Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?

( views:213, downloads:0 )

Author:: No author available

Journal Title:: CHINESE MEDICAL JOURNAL

Issue:: 17

DOI:: 10.3760/cma.j.issn.0366-6999.2010.17.033

Key Word:: febuxostat;reactive oxygen species;xanthine oxidase inhibitors;chronic heart failure;signaling pathways

Abstract： @@ Heart failure is currently one of the most common and most cost-intensive of the chronic diseases.1 The main cause of chronic heart failure (CHF) is the abnormalities of both cardiac contractile performance and myocardial energy metabolism. Elevated levels of reactive oxygen species (ROS) have been proposed to contribute to both of them. Xanthine oxidoreductase (XO)is a major source of ROS in the cardiovascular system.

Reference

[1]S, Neubauer,M, Horn,M, Cramer,etc.Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.[J].1997,96.
[2]Berry CE,Hare JM.Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.[J].2004,555(Pt.3).
[3]Ferdinandy P,Panas D,Schulz R.Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts.[J].1999,276(6 Pt.2).
[4]Joseph Bonaventura,Andrew Gow.NO and superoxide: Opposite ends of the seesaw in cardiac contractility[J].2004,101(47).
[5]T, Minaga,K, Takeda,T, Nakamura,etc.Effect of xanthine oxidase inhibitor on myocardial ischemia.[J].1900,11.
[6]Schumacher HR Jr,MacDonald PA,Eustace D,etc.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.[J].2005,353(23).
[7]N G, Pérez,W D, Gao,E, Marbán.Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors.[J].1998,83.
[8]Hou M,Bache RJ,Hu Q,etc.Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure.[J].2006,48(5).
[9]Kwon SH,Pimentel DR,Remondino A,etc.H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways.[J].2003,35(6).
[10]Sabri A,Hughie HH,Lucchesi PA.Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes.[J].2003,5(6).
[11]Harrison R,de-Jong JW,de-Jonge R,etc.Enhanced expression and activity of xanthine oxidoreductase in the failing heart.[J].2000,32(11).
[12]Khalid M, Minhas,Roberto M, Saraiva,Karl H, Schuleri,etc.Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy.[J].2006,98(2).
[13]Ulf Ekelund,Robert Harrison,Ori Shokek,etc.Intravenous Allopurinol Decreases Myocardial Oxygen Consumption and Increases Mechanical Efficiency in Dogs With Pacing-Induced Heart Failure[J].1999,85(5).
[14]Yamaguchi O,Tada M,Matsumura Y,etc.Involvement of Reactive Oxygen Species-mediated NF- kappa B Activation in TNF- alpha -induced Cardiomyocyte Hypertrophy.[J].2002,34(2).
[15]Higuchi Y,Tada M,Matsumura Y,etc.The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model.[J].2002,39(5).
[16]Z, Mallat,I, Philip,M, Lebret,etc.Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure.[J].1998,97.
[17]Jan Lehotsky,Peter Kaplan,Eva Babusikova,etc.Free radical-induced protein modification and inhibition of Ca~(2+)-ATPase of cardiac sarcoplasmic reticulum[J].2003,248(1).
[18]F, Leyva,S D, Anker,I F, Godsland,etc.Uric acid in chronic heart failure: a marker of chronic inflammation.[J].1998,19.
[19]Ukai T,Cheng CP,Tachibana H,etc.Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure.[J].2001,103(5).
[20]Stefan Anker,Wolfram Doehner,Mathias Rauchhaus,etc.Uric Acid and Survival in Chronic Heart FailureValidation and Application in Metabolic, Functional, and Hemodynamic Staging[J].2003,107(15).
[21]Amado LC,Brawn J,Xie J,etc.Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure.[J].2005,39(3).
[22]Gonzalez DR,Raju SV,Tejani AD,etc.Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling.[J].2004,101(45).
[23]Doehner W,Anker SD.Uric acid in chronic heart failure.[J].2005,25(1).
[24]M A, Becker,J, Kisicki,R, Khosravan,etc.Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.[J].2004,23(8-9).
[25]Alec Vahanian.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008[J].2008,29(19).
[26]Khosravan R,Grabowski BA,Wu JT,etc.Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.[J].2006,45(8).
[27]Ceconi C,Percoco GF,Mele D,etc.Oxidative stress during myocardial ischaemia and heart failure.[J].2004,10(14).
[28]Vernillet L,Joseph Ridge N,Wu JT,etc.Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.[J].2005,12(1).
[29]Yokota M,Kimata H,Hashimoto K,etc.Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters.[J].2008,14(3).